CPRX - Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)
2024-04-06 07:52:16 ET
Summary
- Catalyst Pharmaceuticals' stock has performed well, up approximately 20% since my previous article's tepid "Buy" rating.
- Its stock price is no longer depressed, and its guidance for 2024 is unremarkable, leading to a downgrading to a "Hold".
- Acquisition of commercial rights to FYCOMPA has provided it with a second revenue stream, but the deal's financial viability remains uncertain.
This is my sixth Catalyst ( CPRX ) article. I rated it as a tepid "Buy" in my most recent 07/2023's "Catalyst Pharmaceuticals: A New Catalyst Tilts The Scales - Just Barely" (" Just Barely "). Since Just Barely, Catalyst has performed well, up ~20%....
Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)